NEWS & UPDATES

September 1, 2010. gmsbiotech will launch, October 1, 2010, the beta testing of its HLA Chip technology in the ASHI-certified laboratories of The Methodist Hospital, Houston Texas, under the direction of Dr Geoffrey Land, Medical Director, Histocompatibility/Microbiology and Professor of Pathology & Laboratory Medicine and President of ASHI. This bets test program will be used to validate the technology, for low cost HLA typing in the context of routine workflow in an ASHI-certified tissue typing laboratory.

August 1, 2010. gmsbiotech launched beta testing of its HLA Chip technology in the ASHI-certified laboratories of The New Zealand Blood Labs, Auckland NZ, under the direction of Dr Paul Dunn. This beta test program will be used to validate the technology, for low cost HLA typing in the context of routine workflow in an ASHI-certified tissue typing laboratory.
July 1, 2010.Genomics USA will conduct its business (DBA) in the name of gms-biotech (Genetics Made Simple) to reflect the simplifications inherent in its technologies for complex, population-scale genetics.

February 23, 2010. The US Patent and Trademark Office has awarded Genomics USA a patent: Hogan ME, JayaramanK, MitraR & Eggers RH.Population Scale HLA Typing and Methods Thereof.USPatent No. 7,667,026.This US patent confirms broad protection to the design of its HLA-Chip products.

November 3, 2009. Genomics USA presented its HLA-Chip technology at the 35th annual meeting of The American Society of Histocompatibilityand Immunogenetics(ASHI). This appearance was a springboard event for Genomics USA to obtain ASHI certification of its HLA-Chip technology. The Company now believes this certification may be obtained in the fourth quarter of 2010. ASHI certification will strengthen the intended application and approval by the U.S. Food and Drug Administration for the HLA-Chip product by 2012. The HLA-Chip product consists of gene probes for the analysis of genetic compatibility in marrow, stem cell & solid organ transplantation: the well-known backbone of transplantation medicine.

August 15, 2009. The National Institute of Allergy and Infectious Disease has awarded a three year, Phase II SBIR Competitive Continuation grant to Genomics USA, to support ASHI & FDA approval of its "HLA-Chip" Product for low cost, population-scale HLA-typing. This Phase II Continuation Grant award is significant, in that such programs must have already completed a successful Phase II, and the resulting product must stand ready, during the three-year Continuation Phase, for validation and approval by a Federal regulatory agency such as the FDA.

August 15, 2009. The National Institute of Allergy and Infectious Disease has awarded a two year, Phase I Advanced Technology SBIR grant to Genomics USA, to support development of an "AIDS-Chip" to be used for population scale analysis of the personalized risk of HIV infection and personalized response to AIDS therapy, based on variation in the human immune system. This product development program is an important milestone for GenUSA, in that it parallels the company's move into the personalized genetic medicine of vaccines and chemical therapeutics.

April 8, 2009. The US Patent and Trademark Office has awarded to Genomics USA, the US Patent 7,354,710, "Methods and devices based upon a novelform of the nucleic acid duplex on a surface". This patent comprises an important base for the Genomics USA technology platform.

Q3-2008. Dr. Paul Dunn has joined the Genomics USA team as ASHI Director and HLA Advisor.

Q3-2008. Genomics USA received a Notice of Intent to grant the European patent application No. 02748133.2 titled “Methods and Devices Based Upon A Novel Form of Nucleic Acid Duplex On A Surface”.

Q2-2008. Genomics USA was awarded the US patent on April 8, 2008 No. 7354710 titled “ Methods and Devices Based Upon A Novel Form of Nucleic Acid Duplex On A Surface”.

Q3-2006. GenUSA receives funding of about $3 million for 3 years effective from September 1, 2006 for its Phase 2 grant "Population-scaleHLA typing for home land defense.

Q2-2006. GenUSA receives funding from QuantRxBioMedicalCorporation.

Q2-2004. GenUSA SBIR Phase I grant "Population-scale HLA typing for home land defense," is funded by NIAID, effective May 1, 2004. for $498,500.

Q3-2003. GenUSA is awarded a seed grant from Chicago ITEC to continue its feasibility studies.